SCHEMBL4678097

SCHEMBL4678097

O=C(O)C(O)=CC(=O)c1ccn(Cc2ccc(F)cc2)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.45
RAB9A P51151 5/20 0.45
ALDH1A1 P00352 2/20 0.45
LMNA P02545 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
NPSR1 Q6W5P4 2/20 0.44
TSHR P16473 1/20 0.44
HTT P42858 1/20 0.44
CACNA1G O43497 4/20 0.44
CACNA1H O95180 4/20 0.44
CACNA1I Q9P0X4 4/20 0.44
HDAC1 Q13547 3/20 0.44
HDAC7 Q8WUI4 1/20 0.44
TP53 P04637 1/20 0.43
CA12 O43570 2/20 0.42
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
CA9 Q16790 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.40
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4671228 0.88 HDAC1 (0.50) NPC1RAB9AALDH1A1LMNASMN1; SMN2
SCHEMBL4672568 0.87 CACNA1G (0.47) NPC1RAB9AALDH1A1LMNASMN1; SMN2
SCHEMBL4673761 0.87 HDAC1 (0.39) NPC1RAB9AALDH1A1LMNASMN1; SMN2
SCHEMBL4676243 0.85 HDAC1 (0.40) NPC1RAB9AALDH1A1LMNASMN1; SMN2
SCHEMBL4675432 0.85 L3MBTL1 (0.52) NPC1RAB9AALDH1A1SMN1; SMN2HDAC1
SCHEMBL4671336 0.85 ALDH1A1 (0.43) NPC1RAB9AALDH1A1LMNASMN1; SMN2
SCHEMBL4676077 0.84 CACNA1G (0.50) NPC1RAB9AALDH1A1CACNA1GCACNA1H
SCHEMBL30890833 0.82 NPC1 (0.52) NPC1RAB9AALDH1A1LMNASMN1; SMN2
SCHEMBL4695940 0.80 KMT2A (0.50) NPC1RAB9AALDH1A1LMNASMN1; SMN2
SCHEMBL4675309 0.78 NPC1 (0.39) NPC1RAB9AALDH1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 NPC1 934/4885RAB9A 2021/4885ALDH1A1 980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.